Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LISETTE DELGADO SANCHEZ

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1558523050
CMS profile
70113
Location
NAPLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,534.00

175 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,534.00 175

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 4; records 151–175 of 175 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LISETTE DELGADO SANCHEZ

NPI 1558523050 · CMS profile ID 70113

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

NAPLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–175 of 175 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558523050?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LISETTE DELGADO SANCHEZ, NPI 1558523050, CMS profile ID 70113. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–175 of 175 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558523050?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LISETTE DELGADO SANCHEZ, NPI 1558523050, CMS profile ID 70113. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–175 of 175 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558523050?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LISETTE DELGADO SANCHEZ, NPI 1558523050, CMS profile ID 70113, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–175 of 175 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1558523050?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

175 matching records · $3,534.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 175 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–175 of 175.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $15.8102/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670367823 CMS
AstraZeneca Pharmaceuticals LP $24.3102/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685858333 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.1802/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700268821 CMS
GENZYME CORPORATION $17.8602/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693921069 CMS
AstraZeneca Pharmaceuticals LP $22.2202/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685380895 CMS
GlaxoSmithKline, LLC. $19.4401/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670882089 CMS
AstraZeneca Pharmaceuticals LP $17.0501/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685465425 CMS
Actelion Pharmaceuticals US, Inc. $17.6401/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659739543 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.0201/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700268823 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.0801/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700268825 CMS
Novartis Pharmaceuticals Corporation $23.3701/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659030571 CMS
Mylan Specialty L.P. $21.1701/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694802493 CMS
Grifols USA, LLC $18.9301/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692578681 CMS
GlaxoSmithKline, LLC. $4.3501/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670688147 CMS
Philips Electronics North America Corporation $18.6901/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684057173 CMS
GlaxoSmithKline, LLC. $12.5201/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671097841 CMS
GlaxoSmithKline, LLC. $19.1401/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671429063 CMS
GENZYME CORPORATION $17.5101/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693892529 CMS
AstraZeneca Pharmaceuticals LP $23.3801/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685883171 CMS
Sunovion Pharmaceuticals Inc. $17.4401/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688057873 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.3801/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700268827 CMS
Genentech USA, Inc. $6.5901/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681236335 CMS
GlaxoSmithKline, LLC. $19.5301/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670952457 CMS
AstraZeneca Pharmaceuticals LP $20.3201/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685989831 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $8.2601/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700268829 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,534.00 175
PY2020 $2,589.63 135
PY2021 $2,561.83 131
PY2022 $3,773.47 191
PY2023 $4,461.83 206
PY2024 $5,992.44 180
PY2025 $9,447.60 221

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $705,778.20 232
PY2024 Principal investigator $246,724.53 79
PY2023 Principal investigator $2,292.76 2
PY2022 Principal investigator $115,940.83 67
PY2021 Principal investigator $415,404.11 60
PY2020 Principal investigator $65,828.05 19
PY2019 Principal investigator $14,367.50 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

232 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $1.96 12/31/2025 Non-covered Recipient Entity
Advanced Research For Health Improvement LLC
A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. No dispute reported 06/30/2026 1232928441
Principal investigator 1 Boehringer Ingelheim International GmbH $163.24 12/17/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754154
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 12/17/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754156
Principal investigator 1 Boehringer Ingelheim International GmbH $32.48 12/17/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754158
Principal investigator 1 Boehringer Ingelheim International GmbH $87.40 12/17/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754160
Principal investigator 1 Boehringer Ingelheim International GmbH $21.00 12/17/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754162
Principal investigator 1 Boehringer Ingelheim International GmbH $3.10 12/17/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754164
Principal investigator 1 Boehringer Ingelheim International GmbH $50.00 12/17/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754166
Principal investigator 1 GlaxoSmithKline, LLC. $4,578.50 12/11/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192175431
Principal investigator 1 GlaxoSmithKline, LLC. $4,578.50 12/11/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192177256
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 12/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754138
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 12/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754140
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 12/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754142
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 12/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754144
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $50,007.00 12/01/2025 Non-covered Recipient Entity
Essence MD Research LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220814517
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 12/01/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192175415
Principal investigator 1 Boehringer Ingelheim International GmbH $2.50 11/28/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754186
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 11/28/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754188
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 11/28/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754190
Principal investigator 1 Boehringer Ingelheim International GmbH $2.50 11/24/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754180
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 11/24/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754182
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 11/24/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754184
Principal investigator 1 GlaxoSmithKline, LLC. $3,132.56 11/24/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192179201
Principal investigator 1 Boehringer Ingelheim International GmbH $0.87 11/20/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754112
Principal investigator 1 Boehringer Ingelheim International GmbH $4.72 11/20/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754114
Principal investigator 1 Boehringer Ingelheim International GmbH $0.70 11/20/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754116
Principal investigator 1 Boehringer Ingelheim International GmbH $9.60 11/20/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754118
Principal investigator 1 Boehringer Ingelheim International GmbH $11.39 11/20/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754120
Principal investigator 1 GlaxoSmithKline, LLC. $22,204.61 11/12/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192175427
Principal investigator 1 Boehringer Ingelheim International GmbH $0.87 11/07/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754102
Principal investigator 1 Boehringer Ingelheim International GmbH $4.72 11/07/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754104
Principal investigator 1 Boehringer Ingelheim International GmbH $0.70 11/07/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754106
Principal investigator 1 Boehringer Ingelheim International GmbH $9.60 11/07/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754108
Principal investigator 1 Boehringer Ingelheim International GmbH $11.39 11/07/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754110
Principal investigator 1 GlaxoSmithKline, LLC. $2,880.95 11/07/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192179170
Principal investigator 1 GlaxoSmithKline, LLC. $2,854.57 11/07/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192179179
Principal investigator 1 GlaxoSmithKline, LLC. $3,048.90 11/06/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192123833
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 11/05/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192179187
Principal investigator 1 GlaxoSmithKline, LLC. $14,500.00 11/05/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192179193
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 11/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754130
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 11/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754132
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 11/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754134
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 11/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754136
Principal investigator 1 Boehringer Ingelheim International GmbH $104.94 10/27/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754146
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 10/27/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754148
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 10/27/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754150
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 10/27/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754152
Principal investigator 1 Insmed, Inc. $7,637.49 10/22/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651584
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 10/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754122
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 10/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754124
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 10/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754126
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 10/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754128
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 09/24/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754088
Principal investigator 1 Boehringer Ingelheim International GmbH $4.64 09/24/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754090
Principal investigator 1 GlaxoSmithKline, LLC. $12,097.15 09/18/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192177273
Principal investigator 1 GlaxoSmithKline, LLC. $9,218.14 09/15/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192177277
Principal investigator 1 Insmed, Inc. $13,651.09 09/12/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651578
Principal investigator 1 Boehringer Ingelheim International GmbH $5.01 09/08/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754168
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 09/08/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754170
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 09/08/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754172
Principal investigator 1 Boehringer Ingelheim International GmbH $5.01 09/08/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754174
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 09/08/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754176
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 09/08/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754178
Principal investigator 1 Boehringer Ingelheim International GmbH $1.40 09/04/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754092
Principal investigator 1 Boehringer Ingelheim International GmbH $19.19 09/04/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754094
Principal investigator 1 Boehringer Ingelheim International GmbH $22.78 09/04/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754096
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 09/04/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754098
Principal investigator 1 Boehringer Ingelheim International GmbH $9.44 09/04/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754100
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 09/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754048
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 09/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754066
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 09/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754068
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 09/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754070
Principal investigator 1 GlaxoSmithKline, LLC. $2,029.40 08/27/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192177251
Principal investigator 1 Insmed, Inc. $0.44 08/27/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651546
Principal investigator 1 Insmed, Inc. $0.46 08/27/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651554
Principal investigator 1 Insmed, Inc. $6,888.84 08/27/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651562
Principal investigator 1 Insmed, Inc. $0.92 08/27/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651570
Principal investigator 1 Boehringer Ingelheim International GmbH $104.94 08/26/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754078
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 08/26/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754080
Principal investigator 1 Boehringer Ingelheim International GmbH $16.24 08/26/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754082
Principal investigator 1 Boehringer Ingelheim International GmbH $87.40 08/26/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754084
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/26/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754086
Principal investigator 1 GlaxoSmithKline, LLC. $12,397.67 08/22/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192179183
Principal investigator 1 Insmed, Inc. $0.44 08/21/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651548
Principal investigator 1 Insmed, Inc. $0.92 08/21/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651556
Principal investigator 1 Insmed, Inc. $6,888.84 08/21/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651564
Principal investigator 1 Insmed, Inc. $0.46 08/21/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651572
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,325.00 08/20/2025 Non-covered Recipient Entity
Essence MD Research LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220814515
Principal investigator 1 GlaxoSmithKline, LLC. $2,806.30 08/14/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192177269
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 08/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754052
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 08/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754060
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 08/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754062
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 08/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754064
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 07/28/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754072
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 07/28/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754074
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 07/28/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754076
Principal investigator 1 Insmed, Inc. $0.44 07/15/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651550
Principal investigator 1 Insmed, Inc. $0.46 07/15/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651558
Principal investigator 1 Insmed, Inc. $6,888.84 07/15/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651566
Principal investigator 1 Insmed, Inc. $0.46 07/15/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651574
Principal investigator 1 GlaxoSmithKline, LLC. $2,306.95 07/14/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192179174
Principal investigator 1 Insmed, Inc. $0.66 07/02/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651552
Principal investigator 1 Insmed, Inc. $0.46 07/02/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651560
Principal investigator 1 Insmed, Inc. $11,481.40 07/02/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651568
Principal investigator 1 Insmed, Inc. $1.38 07/02/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651576
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 07/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754050
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 07/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754054
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 07/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754056
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 07/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754058
Principal investigator 1 Insmed, Inc. $0.66 06/26/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651522
Principal investigator 1 Insmed, Inc. $11,481.40 06/26/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651532
Principal investigator 1 Insmed, Inc. $1.38 06/26/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651542
Principal investigator 1 Insmed, Inc. $0.92 06/26/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651544
Principal investigator 1 CSL Behring $1,500.00 06/25/2025 Non-covered Recipient Entity
Essence MD Research LLC
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252669564
Principal investigator 1 CSL Behring $2,000.00 06/25/2025 Non-covered Recipient Entity
Essence MD Research LLC
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252669566
Principal investigator 1 CSL Behring $2,593.00 06/25/2025 Non-covered Recipient Entity
Essence MD Research LLC
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252669568
Principal investigator 1 CSL Behring $3,000.00 06/25/2025 Non-covered Recipient Entity
Essence MD Research LLC
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252669570
Principal investigator 1 CSL Behring $8,031.00 06/25/2025 Non-covered Recipient Entity
Essence MD Research LLC
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252669572
Principal investigator 1 Boehringer Ingelheim International GmbH $4.20 06/24/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754046
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 06/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754014
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 06/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754016
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 06/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754018
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 06/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754026
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 06/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754032
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 05/27/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754034
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 05/27/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754036
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 05/27/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754038
Principal investigator 1 Boehringer Ingelheim International GmbH $9.28 05/27/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754040
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 05/27/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754042
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/27/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754044
Principal investigator 1 GlaxoSmithKline, LLC. $16,714.27 05/27/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192175408
Principal investigator 1 GlaxoSmithKline, LLC. $5,693.04 05/22/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192177265
Principal investigator 1 Insmed, Inc. $0.66 05/20/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651524
Principal investigator 1 Insmed, Inc. $0.46 05/20/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651526
Principal investigator 1 Insmed, Inc. $11,481.40 05/20/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651534
Principal investigator 1 Insmed, Inc. $0.92 05/20/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651536
Principal investigator 1 GlaxoSmithKline, LLC. $1,308.88 05/15/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192175403
Principal investigator 1 GlaxoSmithKline, LLC. $3,029.60 05/15/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192175419
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 05/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754006
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 05/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754008
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 05/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754010
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 05/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754012
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 05/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754020
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 05/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754022
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 05/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754024
Principal investigator 1 Boehringer Ingelheim International GmbH $799.00 05/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754028
Principal investigator 1 Boehringer Ingelheim International GmbH $799.00 05/01/2025 Non-covered Recipient Entity
Millennium Physicians Group-Naples Multi Specialty
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220754030
Principal investigator 1 GlaxoSmithKline, LLC. $4,304.50 04/24/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192177253
Principal investigator 1 AstraZeneca Pharmaceuticals LP $40,764.50 04/23/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER, PA
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1185540293
Principal investigator 1 Insmed, Inc. $0.88 04/09/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651514
Principal investigator 1 Insmed, Inc. $16,073.96 04/09/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651518
Principal investigator 1 Insmed, Inc. $0.46 04/09/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651528
Principal investigator 1 Insmed, Inc. $1.38 04/09/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651538
Principal investigator 1 Insmed, Inc. $0.88 04/03/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651516
Principal investigator 1 Insmed, Inc. $16,073.96 04/03/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651520
Principal investigator 1 Insmed, Inc. $1.38 04/03/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651530
Principal investigator 1 Insmed, Inc. $0.92 04/03/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651540
Principal investigator 1 Insmed, Inc. $240.00 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651442
Principal investigator 1 Insmed, Inc. $480.00 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651444
Principal investigator 1 Insmed, Inc. $480.00 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651446
Principal investigator 1 Insmed, Inc. $45.00 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651448
Principal investigator 1 Insmed, Inc. $45.00 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651450
Principal investigator 1 Insmed, Inc. $45.00 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651452
Principal investigator 1 Insmed, Inc. $45.00 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651454
Principal investigator 1 Insmed, Inc. $250.00 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651456
Principal investigator 1 Insmed, Inc. $200.00 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651458
Principal investigator 1 Insmed, Inc. $534.24 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651460
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651462
Principal investigator 1 Insmed, Inc. $534.24 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651464
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651466
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651468
Principal investigator 1 Insmed, Inc. $534.24 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651470
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651472
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651474
Principal investigator 1 Insmed, Inc. $534.24 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651476
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651478
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651480
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651482
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651484
Principal investigator 1 Insmed, Inc. $250.00 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651486
Principal investigator 1 Insmed, Inc. $534.24 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651488
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651490
Principal investigator 1 Insmed, Inc. $534.24 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651492
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651494
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651496
Principal investigator 1 Insmed, Inc. $534.24 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651498
Principal investigator 1 Insmed, Inc. $534.24 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651500
Principal investigator 1 Insmed, Inc. $350.00 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651502
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651504
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651506
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651508
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651510
Principal investigator 1 Insmed, Inc. $50.40 03/31/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651512
Principal investigator 1 AstraZeneca Pharmaceuticals LP $187,490.00 03/21/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1185540295
Principal investigator 1 Insmed, Inc. $0.44 03/17/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651382
Principal investigator 1 Insmed, Inc. $6,888.84 03/17/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651394
Principal investigator 1 Insmed, Inc. $0.46 03/17/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651410
Principal investigator 1 Insmed, Inc. $0.92 03/17/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651420
Principal investigator 1 Insmed, Inc. $0.44 03/06/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651384
Principal investigator 1 Insmed, Inc. $6,888.84 03/06/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651396
Principal investigator 1 Insmed, Inc. $0.92 03/06/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651412
Principal investigator 1 Insmed, Inc. $0.46 03/06/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651422
Principal investigator 1 GlaxoSmithKline, LLC. $3,605.53 02/26/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192123827
Principal investigator 1 Insmed, Inc. $0.88 02/25/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651386
Principal investigator 1 Insmed, Inc. $16,073.96 02/25/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651398
Principal investigator 1 Insmed, Inc. $0.46 02/25/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651400
Principal investigator 1 Insmed, Inc. $0.92 02/25/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651414
Principal investigator 1 GlaxoSmithKline, LLC. $3,832.69 02/24/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192177261
Principal investigator 1 Insmed, Inc. $1,458.32 02/21/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651434
Principal investigator 1 Insmed, Inc. $306.18 02/21/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651436
Principal investigator 1 Insmed, Inc. $306.18 02/21/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651438
Principal investigator 1 Insmed, Inc. $198.45 02/21/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651440
Principal investigator 1 GlaxoSmithKline, LLC. $5,842.20 02/06/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192175411
Principal investigator 1 GlaxoSmithKline, LLC. $48,134.18 01/30/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192179196
Principal investigator 1 GlaxoSmithKline, LLC. $13,317.88 01/28/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192175422
Principal investigator 1 Insmed, Inc. $0.44 01/28/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651376
Principal investigator 1 Insmed, Inc. $6,888.84 01/28/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651388
Principal investigator 1 Insmed, Inc. $0.46 01/28/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651402
Principal investigator 1 Insmed, Inc. $0.46 01/28/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651416
Principal investigator 1 Insmed, Inc. $1,458.32 01/24/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651424
Principal investigator 1 Insmed, Inc. $1,458.32 01/24/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651426
Principal investigator 1 Insmed, Inc. $1,458.32 01/24/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651428
Principal investigator 1 Insmed, Inc. $589.68 01/24/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651430
Principal investigator 1 Insmed, Inc. $306.18 01/24/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651432
Principal investigator 1 Insmed, Inc. $0.66 01/16/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651378
Principal investigator 1 Insmed, Inc. $4,592.56 01/16/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651390
Principal investigator 1 Insmed, Inc. $0.46 01/16/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651404
Principal investigator 1 Insmed, Inc. $1.38 01/16/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651418
Principal investigator 1 Insmed, Inc. $0.66 01/09/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651380
Principal investigator 1 Insmed, Inc. $11,481.40 01/09/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651392
Principal investigator 1 Insmed, Inc. $1.38 01/09/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651406
Principal investigator 1 Insmed, Inc. $0.92 01/09/2025 Non-covered Recipient Entity
ESSENCE MD RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651408